Anti-HER2/ErbB2 antibody

Anti-HER2/ErbB2 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit polyclonal to HER2/ErbB2

WB

Human ERBB2

NEU antibody; NGL antibody; HER2 antibody; TKR1 antibody; CD340 antibody; HER-2 antibody; MLN19 antibody; HER-2/neu antibody; Neu antibody; HER2 antibody; HER-2 antibody; c-neu antibody; Erbb-2 antibody; c-erbB2 antibody; mKIAA3023 antibody; CD340 antibody; c-erbB2 antibody; c-erbB-2 antibody; c-neu antibody; Erbb2 antibody; ERBB2 antibody; Erbb-2 antibody; HER2 antibody; HER2 antibody; HER-2 antibody; HER-2 antibody; HER-2/neu antibody; mKIAA3023 antibody; Neu antibody; NEU antibody; NGL antibody; RP23-355L10.8 antibody; TKR1 antibody

Rabbit IgG

Produced in rabbits immunized with a synthetic peptide corresponding to the center region of the human ERBB2 , and purified by antigen affinity chromatography.

Polyclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein, and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.

• Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.